C91.10: Chronic lymphocytic leukemia of B-cell type not having achieved remission
C91.10, chronic lymphocytic leukemia of B-cell type not having achieved remission, is listed as a covered diagnosis in 19 Medicare billing and coding articles that apply to 109 HCPCS Level II codes, including J1569 (Injection, immune globulin, (gammagard liquid/gammagard…), J1561 (Injection, immune globulin, (gamunex-c/gammaked)…), J1459 (Injection, immune globulin (privigen), intravenous…). 4 of these codes have a 2026 DMEPOS fee schedule amount; E0783 pays $9,917.33 to $11,667.45 (NU) depending on the state. The articles come from 7 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with C91.10 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| J1569 | Injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg | Special coverage instructions apply | — | 7 |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Special coverage instructions apply | — | 7 |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | Carrier judgment | — | 7 |
| J1557 | Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg | Carrier judgment | — | 7 |
| J1556 | Injection, immune globulin (bivigam), 500 mg | Carrier judgment | — | 7 |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Carrier judgment | — | 7 |
| J1566 | Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg | Special coverage instructions apply | — | 7 |
| J1552 | Injection, immune globulin (alyglo), 500 mg | Carrier judgment | — | 6 |
| J1554 | Injection, immune globulin (asceniv), 500 mg | Carrier judgment | — | 6 |
| J1576 | Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg | Special coverage instructions apply | — | 5 |
| J1577 | Injection, immune globulin (qivigy), 100 mg | Carrier judgment | — | 5 |
| J1572 | Injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg | Special coverage instructions apply | — | 4 |
| J1553 | Injection, immune globulin (yimmugo), 100 mg | Carrier judgment | — | 3 |
| J1599 | Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg | Carrier judgment | — | 4 |
| J1575 | Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin | Carrier judgment | — | 3 |
| J1559 | Injection, immune globulin (hizentra), 100 mg | Carrier judgment | — | 2 |
| J1555 | Injection, immune globulin (cuvitru), 100 mg | Carrier judgment | — | 2 |
| J1558 | Injection, immune globulin (xembify), 100 mg | Carrier judgment | — | 2 |
| J1551 | Injection, immune globulin (cutaquig), 100 mg | Carrier judgment | — | 2 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Special coverage instructions apply | — | 3 |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Special coverage instructions apply | — | 3 |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Special coverage instructions apply | — | 3 |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | Special coverage instructions apply | — | 3 |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | Special coverage instructions apply | — | 3 |
| J0890 | Injection, peginesatide, 0.1 mg (for esrd on dialysis) | Carrier judgment | — | 3 |
84 more codes are listed. See every code with payment by region in Caduvo.
Medicare policy articles listing C91.10
- A57187: Billing and Coding: Immune Globulin Intravenous (IVIg) (Noridian Healthcare Solutions, LLC (MAC - Part A, MAC - Part B); 13 Level II codes). LCD with the same title: L34314
- A56779: Billing and Coding: Intravenous Immune Globulin (CGS Administrators, LLC (MAC - Part A, MAC - Part B); 9 Level II codes). LCD with the same title: L33610, L35891
- A56786: Billing and Coding: Immune Globulin (Novitas Solutions, Inc. (MAC - Part A, MAC - Part B); 18 Level II codes). LCD with the same title: L34007, L35093
- A57778: Billing and Coding: Immune Globulin (First Coast Service Options, Inc. (MAC - Part A, MAC - Part B); 18 Level II codes). LCD with the same title: L34007, L35093
- A56718: Billing and Coding: Intravenous Immunoglobulin (IVIG) (Palmetto GBA (MAC - Part A, MAC - Part B); 13 Level II codes). LCD with the same title: L34580
- A59105: Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG) (Wellpoint Federal (MAC - Part A, MAC - Part B); 11 Level II codes). LCD with the same title: L39314
- A56380: Billing and Coding: Rituximab (Palmetto GBA (MAC - Part A, MAC - Part B); 6 Level II codes). LCD with the same title: L35026
- A59101: Billing and Coding: Off-label Use of Rituximab and Rituximab Biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B); 4 Level II codes). LCD with the same title: L38920, L39297
- A58982: Billing and Coding: Erythropoiesis Stimulating Agents (Palmetto GBA (MAC - Part A, MAC - Part B); 9 Level II codes). LCD with the same title: L39237
- A57554: Billing and Coding: Immune Globulins (WPS Insurance Corporation (MAC - Part A, MAC - Part B); 20 Level II codes). LCD with the same title: L34771
- A54768: Billing and Coding: Cardiac Blood Pool Imaging (Multiple Gated Acquisition Scanning- MUGA, Ventriculography) When Performed in Conjunction with Cardiotoxic Chemotherapy (Palmetto GBA (MAC - Part A, MAC - Part B); 5 Level II codes)
- A52479: Oral Anticancer Drugs - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC); 8 Level II codes). LCD with the same title: L33826
- A56462: Billing and Coding: Erythropoiesis Stimulating Agents (ESA) (CGS Administrators, LLC (MAC - Part A, MAC - Part B); 7 Level II codes). LCD with the same title: L34356
- A56748: Billing and Coding: White Cell Colony Stimulating Factors (Palmetto GBA (MAC - Part A, MAC - Part B); 16 Level II codes). LCD with the same title: L37176
- A52480: Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC); 19 Level II codes). LCD with the same title: L33827
4 more articles list C91.10.
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other C91 diagnoses (Lymphoid leukemia)
- C91.11 — Chronic lymphocytic leukemia of B-cell type in remission
- C91.12 — Chronic lymphocytic leukemia of B-cell type in relapse
- C91.00 — Acute lymphoblastic leukemia not having achieved remission
- C91.01 — Acute lymphoblastic leukemia, in remission
- C91.02 — Acute lymphoblastic leukemia, in relapse
- C91.30 — Prolymphocytic leukemia of B-cell type not having achieved remission
- C91.31 — Prolymphocytic leukemia of B-cell type, in remission
- C91.32 — Prolymphocytic leukemia of B-cell type, in relapse
- C91.40 — Hairy cell leukemia not having achieved remission
- C91.41 — Hairy cell leukemia, in remission
- C91.42 — Hairy cell leukemia, in relapse
- C91.50 — Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having…
- C91.51 — Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission
- C91.52 — Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse
- C91.60 — Prolymphocytic leukemia of T-cell type not having achieved remission
- C91.61 — Prolymphocytic leukemia of T-cell type, in remission
- C91.62 — Prolymphocytic leukemia of T-cell type, in relapse
- C91.90 — Lymphoid leukemia, unspecified not having achieved remission
- C91.91 — Lymphoid leukemia, unspecified, in remission
- C91.92 — Lymphoid leukemia, unspecified, in relapse
- C91.A0 — Mature B-cell leukemia Burkitt-type not having achieved remission
- C91.A1 — Mature B-cell leukemia Burkitt-type, in remission
- C91.A2 — Mature B-cell leukemia Burkitt-type, in relapse
- C91.Z0 — Other lymphoid leukemia not having achieved remission
- C91.Z1 — Other lymphoid leukemia, in remission
- C91.Z2 — Other lymphoid leukemia, in relapse
Frequently asked questions
Does Medicare cover C91.10 (Chronic lymphocytic leukemia of B-cell type not having…)?
Medicare covers items and services, not diagnoses. 19 Medicare billing and coding articles list C91.10 as a covered diagnosis for 109 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 C91.10?
The Level II codes from the policies most specific to this diagnosis are J1569 (Injection, immune globulin, (gammagard liquid/gammagard…, 7 articles); J1561 (Injection, immune globulin, (gamunex-c/gammaked)…, 7 articles); J1459 (Injection, immune globulin (privigen), intravenous…, 7 articles); J1557 (Injection, immune globulin, (gammaplex), intravenous…, 7 articles); J1556 (Injection, immune globulin (bivigam), 500 mg, 7 articles). Code choice depends on the item supplied; check each code's descriptor.
What does Medicare pay for equipment billed with C91.10?
Under the 2026 DMEPOS fee schedule (non-rural state fees): E0783 $9,917.33 to $11,667.45 (NU); E0786 $10,969.75 to $11,380.88 (NU); E0782 $5,200.92 to $6,118.73 (NU); E0785 $572.38 to $673.39 (KF). Medicare pays 80% of the allowed amount after the Part B deductible.
Which Medicare policy articles list C91.10?
A57187 (Billing and Coding: Immune Globulin Intravenous (IVIg)); A56779 (Billing and Coding: Intravenous Immune Globulin); A56786 (Billing and Coding: Immune Globulin), and 16 more articles.
What is ICD-10-CM code C91.10?
C91.10 is the ICD-10-CM code for chronic lymphocytic leukemia of B-cell type not having achieved remission, in category C91 (Lymphoid leukemia), chapter 2: Neoplasms.
Next steps
- Run a reimbursement report for a device billed under J1569
- Watch J1569 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1569
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.